## Alkem Laboratories Limited (ALKEM) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Alkem Laboratories Limited (ALKEM) is a pharmaceutical company listed on the National Stock Exchange of India (NSE) on December 23, 2015.  It operates within the Pharmaceuticals & Biotechnology sector, specifically focusing on pharmaceuticals.  The company's exact positioning within the sector requires further research beyond the provided data, but its presence on the NSE indicates a significant market share and established presence.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹5,425.00       | Closed at ₹5,427.50; Intraday low of ₹5,404.80                     |
| Percentage Change (PChange) | -1.26%          | Compared to the previous close of ₹5,494.25                         |
| Pre-Open Activity          | ₹5,535.00       |  Opened higher than the previous close, indicating initial buying pressure.  However, the final price closed lower. |
| Week High                    | ₹6,439.90       | High volatility observed during the week.                             |
| Week Low                     | ₹4,407.05       | Significant price fluctuation.                                        |
| VWAP                        | ₹5,468.69       | Volume Weighted Average Price suggests a slightly higher average trading price. |
| Sector PE                   | 29.68           | Industry average Price-to-Earnings ratio.                           |
| Symbol PE                   | 30.4            | ALKEM's Price-to-Earnings ratio, slightly higher than the sector average. |
| Delivery Percentage         | 50.38%          | Moderate delivery percentage, indicating a mix of long-term and short-term investors. |
| Market Depth                | Insufficient Data | The provided order book data is insufficient for a meaningful depth analysis.  Further data is needed. |


**3. Financial Performance:**

The provided financial data shows a mixed performance over the past five quarters.  While revenue and profit after tax have generally increased, there's significant quarter-to-quarter fluctuation.  The impact of exceptional items (cybersecurity incident and impairment loss) needs careful consideration.

| Quarter      | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | Diluted EPS (₹) |
|--------------|-------------|-------------|-----------------------|-----------------|
| Q1 2024       | 244,916     | 204,763     | 32,497.07             | 27.18            |
| Q2 2024       | 260,620     | 196,526     | 58,325                | 48.78            |
| Q3 2024       | 299,216     | 222,449     | 69,758                | 58.34            |
| Q4 2023       | 259,025     | 200,456     | 50,423                | 42.17            |
| Q3 2023       | 269,643     | 205,771     | 64,651                | 54.07            |


**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and others.  The provided data is insufficient for a comprehensive ratio analysis.

**4. Corporate Actions and Announcements:**

ALKEM has a history of consistent dividend payouts, both interim and final.  Recent announcements include board meetings to discuss financial results and a final dividend of ₹5 per share (ex-date August 9, 2024).  There are also several announcements related to acquisitions, slump sales, and analyst meetings, suggesting active corporate activity.  However, the impact of these announcements on the stock price requires further investigation.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023  | 56.74                        | 43.26      | 0.00               | 100.00    |
| 31-Dec-2023  | 56.74                        | 43.26      | 0.00               | 100.00    |
| 31-Mar-2024  | 56.74                        | 43.26      | 0.00               | 100.00    |
| 30-Jun-2024  | 56.38                        | 43.62      | 0.00               | 100.00    |
| 30-Sep-2024  | 55.66                        | 44.34      | 0.00               | 100.00    |

Promoter shareholding has slightly decreased over the past year, while public shareholding has correspondingly increased. This warrants further investigation into the reasons behind this shift.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 29.8% further confirms this.  Risks include the impact of exceptional items on future profitability, potential regulatory changes within the pharmaceutical industry, and general market fluctuations.  The risk-reward profile is currently high risk, high reward due to the volatility and potential for growth.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Generally increasing revenue and profit after tax (excluding exceptional items).
* Active corporate actions suggesting growth initiatives.

**8. Disadvantages and Risks:**

* High volatility.
* Significant quarter-to-quarter fluctuations in financial performance.
* Impact of exceptional items (cybersecurity incident and impairment loss) on future profitability.
* Potential regulatory risks within the pharmaceutical sector.
* Decreasing promoter holding.

**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The current price is near the lower end of its recent range, and short-term price movements are unpredictable due to high volatility.  Waiting for clearer trends is advisable.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the company's ability to address the issues highlighted in the financial statements (exceptional items) and maintain consistent growth.  Further monitoring of financial performance and corporate actions is necessary.

* **Long-term (1 year and beyond): Hold/Buy (with caution).**  The long-term prospects depend on the company's ability to sustain growth within the pharmaceutical sector.  However, the decreasing promoter holding is a concern that needs to be addressed before a strong buy recommendation can be given.  Further due diligence is recommended.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 6/10 (Mixed performance, impacted by exceptional items)
* Market Performance: 7/10 (High volatility, but generally positive trends)
* Volatility and Risk: 4/10 (High volatility presents significant risk)
* Corporate Actions & Governance: 8/10 (Consistent dividends, active corporate activity)
* Shareholding Patterns: 5/10 (Decreasing promoter holding is a concern)

**Analysis Score (out of 10): 8/10**

* Completeness and Data Utilization: 9/10 (Most data utilized effectively)
* Accuracy and Clarity: 8/10 (Analysis is clear, but some limitations due to data constraints)
* Professional Formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, ALKEM presents a mixed investment opportunity.  While the company shows potential for growth, the high volatility and recent negative events (cybersecurity incident, impairment loss, decreasing promoter holding) introduce significant risk.  A "Hold" recommendation is given for the short and medium term, allowing for further monitoring of the company's performance and addressing the identified risks.  A cautious "Hold/Buy" recommendation is given for the long term, contingent upon further due diligence and a clearer understanding of the long-term growth strategy and the reasons behind the decreasing promoter holding.  Investors should exercise caution and consider their own risk tolerance before making any investment decisions.  Additional research beyond the provided data is strongly recommended.
